Business Wire · SMMT · October 21, 2026

Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

Get the app for more

Explore stock news, insights and company research.